Lipid A, mAb 26-5
The monoclonal antibody 26-5 recognizes lipid A. The lipid A domain of lipopolysaccharide (LPS) is a
unique, glucosamine-based phospholipid that makes up the outer monolayer of the outer membrane of
most gram-negative bacteria.
Lipid A is responsible for the endotoxic activities of LPS, and a heteropolysaccharide. The
heteropolysaccharide generally consists of an oligosaccharide termed the core region. This core region
is in some bacterial families composed of repeating oligosaccharide units, the so-called O chain. The
lipid A moiety of LPS is detected by the TLR4/MD2 receptor of the mammalian innate immune system.
Picomolar levels of lipid A induce macrophages to synthesize potent mediators of inflammation, such as
TNF-α and IL-1β. Furthermore, lipid A activates the production of costimulatory molecules required for
adaptive immunity and stimulates tissue factor production in mononuclear and endothelial cells. All
these events are desirable for clearing local infections.
You may also like…
You may be interested in…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis